STOCK TITAN
  1. Home
  2. Sec-filings
  3. DARE
  4. [Form 4] Dare Bioscience, Inc. Insider Trading Activity

Dare Bioscience (DARE) grants 38,862 RSUs to board director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

RASTETTER WILLIAM H reported acquisition or exercise transactions in this Form 4 filing.

Dare Bioscience director William H. Rastetter received an equity grant of 38,862 restricted stock units (RSUs). The RSUs were granted in lieu of cash compensation for his service on the board of directors and its committees, at a stated price of $0.00 per share. Each RSU represents a contingent right to receive one share of common stock upon vesting, which occurs on January 4, 2027. Following this grant, he directly holds 39,721 shares of Dare Bioscience common stock.

Positive

  • None.

Negative

  • None.
Insider RASTETTER WILLIAM H
Role null
Type Security Shares Price Value
Grant/Award Common stock 38,862 $0.00 --
Holdings After Transaction: Common stock — 39,721 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 38,862 units Equity grant to director in lieu of cash compensation
Grant price per share $0.00 per share Stated transaction price for the RSU award
Total shares after grant 39,721 shares Director’s direct Dare Bioscience common stock holdings post-transaction
RSU vesting date January 4, 2027 Date when RSUs convert to shares if conditions are met
restricted stock units ("RSU") financial
"Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation"
cash compensation financial
"RSU granted to the reporting person in lieu of cash compensation for service on the issuer's board"
board of directors financial
"cash compensation for service on the issuer's board of directors and its committees"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
vests financial
"Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RASTETTER WILLIAM H
(Last)(First)(Middle)
3655 NOBEL DRIVE
SUITE 260
(Street)
SAN DIEGO CALIFORNIA 92122
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Dare Bioscience, Inc. [ DARE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common stock06/30/2026A38,862(1)A$039,721D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares underlying restricted stock units ("RSU") granted to the reporting person in lieu of cash compensation for service on the issuer's board of directors and its committees. Each RSU represents a contingent right to receive one share when vested. The RSUs vests on January 4, 2027.
Remarks:
/s/ Sabrina Martucci Johnson, Attorney-in-fact07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Dare Bioscience (DARE) report for William H. Rastetter?

Dare Bioscience reported that director William H. Rastetter received 38,862 restricted stock units as compensation. These RSUs are granted in lieu of cash for his service on the board and its committees, expanding his equity-based stake in the company.

How many Dare Bioscience shares does William H. Rastetter hold after this Form 4 transaction?

After the RSU grant, William H. Rastetter directly holds 39,721 shares of Dare Bioscience common stock. This total reflects the addition of 38,862 restricted stock units awarded as compensation, which convert into shares when they vest.

What are the key terms of the 38,862 RSUs granted by Dare Bioscience to its director?

The 38,862 RSUs granted to William H. Rastetter represent a right to receive one Dare Bioscience common share per unit. They were issued at a stated price of $0.00 per share and will fully vest on January 4, 2027, subject to the grant conditions.

Why did Dare Bioscience grant RSUs instead of cash to director William H. Rastetter?

The RSUs were granted in lieu of cash compensation for William H. Rastetter’s service on Dare Bioscience’s board and committees. This structure replaces cash board fees with equity-based awards, aligning his compensation more directly with the company’s share performance.

When do William H. Rastetter’s Dare Bioscience RSUs vest?

The restricted stock units granted to William H. Rastetter vest on January 4, 2027. On that vesting date, each RSU converts into one share of Dare Bioscience common stock, assuming all conditions attached to the grant are satisfied.